According to a recent study published by the Pennsylvania Health Care Cost Containment Council, the incidence and associated cost of hospital acquired bloodstream infections are increasing at an alarming rate. The Curos Port Protector is designed to reduce patient exposure to the risks of hospital acquired bloodstream infections and help maintain hospital infection control protocols.
“The Curos Port Protector market approval is a significant milestone toward the success of our company,” Bob Rogers, Chief Executive Officer of Ivera Medical said. “It confirms our commitment to assist healthcare providers in their efforts to reduce bloodstream infections caused by touch or airborne contamination of needleless I.V. ports.”
Hospital acquired bloodstream infections dramatically increase a patient’s hospital length of stay, potential mortality and the overall cost of care, according to the Pennsylvania Health Care Cost Containment Council study. Every year in the United States alone, hospital acquired bloodstream infections are estimated to cost the healthcare system over $5 billion.
“At a time when our healthcare system is reducing reimbursements for the treatment of bloodstream infections, the Curos Port Protector will change infection control practices and help healthcare professionals improve patient care,” Jack Saladow, Vice President of Marketing and Sales for Ivera Medical said.
About Ivera Medical Corporation
Ivera Medical develops, manufactures and markets innovative, high quality medical devices to improve healthcare providers’ management and control of patient infections. Ivera Medical products are made in the USA.
www.iveramedical.com
Contact:
Ivera Medical Corporation Jack Saladow Vice President of Marketing and Sales (949) 495-7097 jsaladow@iveramedical.com
Source: Ivera Medical Corporation
